Mouse anti-Human CA19-9 Monoclonal Antibody | anti-CA19-9 antibody

CA19-9

Cat. Num. AAA59174

• Reactivity: Human
• Synonyms: CA19-9, Antibody; CA19-9; anti-CA19-9 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgM
• Clone Number: 121SLE
• Form/Format: CA19-9 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.

• Control: Breast ,Colon, Cervix, Pancreas, Pancreatic Cancer, Breast Carcinoma , Colon Carcinoma, Transitional Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma.
• Immunogen: Purified mucins from ovarian cyst.
• Application: Colon & Gastrointestinal Cancer, Gall Bladder,& Pancreatic Cancer. Reactivity Note
• Frozen sections and cell preparations: The antibody can be used on acetone-fixed frozen sections and acetone- fixed cell preparations.
• Precautions: 1. For professional users only. Results should be interpreted by a qualified medical professional. 2. This product contains <0.1% sodium azide (NaN?) as a preservative. Ensure proper handling procedures are used with this reagent.3. Always wear personal protective equipment such as a laboratory coat, goggles, and gloves when handling reagents. 4. Dispose of unused solution with copious amounts of water. 5. Do not ingest reagent. If reagent is ingested, seek medical advice immediately. 6. Avoid contact with eyes. If contact occurs, flush with large quantities of water. 7. Follow safety precautions of the heating device used for epitope retrieval (TintoRetriever Pressure Cooker or similar). 8. For additional safety information refer to Safety Data Sheet for this product.
• IHC Protocol: 1. Cut and mount 3-5 micron formalin-fixed paraffin-embedded tissues on positively charged slides such as Hydrophilic Plus Slides . 2. Air dry for 2 hours at 58° C. 3. Deparaffinize, dehydrate, and rehydrate tissues.4. Subject tissues to heat induced epitope retrieval (HIER) using a suitable retrieval solution such as ImmunoDNA Retriever with Citrate. 5. Any of three heating methods may be used: a. TintoRetriever Pressure Cooker or EquivalentPlace tissues/slides in a staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA and place on trivet in the pressure cooker. Add 1-2 inches of distilled water to the pressure cooker and turn heat to high. Incubate for 15 minutes. Open and immediately transfer slides to room tempe rature. b. TintoRetriever PT Module or Water Bath Method Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA at 95°-99° C. Incubate for 30-60 minutes. c. Conventional Steamer Method Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA in a steamer, cover and steam for 30-60 minutes. 6. After heat treatment, transfer slides in ImmunoDNA Retriever with Citrate or EDTA to room temperature and let stand for 15-20 minutes. 7. For manual IHC, perform antibody incubation at ambient temperature. For automated IHC methods, perform antibody incubation according to instrument manufacturer’s instructions. 8. Wash slides with ImmunoDNA washer or DI water. 9. Continue IHC protocol. Wash slides between each step with ImmunoDNA washer solution
• Preparation and Storage: Store at 2 -8°C.; This product is table up to the expiration date on the product label. Do not use after expiration date listed on the package lable. Temperature fluctuations should be avoided . Store appropiately when not in sue and avoid prolonged exposure to room temperature conditions.

IHC (Immunohiostchemistry)

Dilution Info

Related Product Information for anti-CA19-9 antibody

CA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category. It was discovered in patients with Colon Cancer and Pancreatic Cancer in 1981. Increased levels of CA19-9 are also found in non-malignant conditions, such as Mirizzi's Syndrome and diseases of the bile duct and liver. The main use of CA19-9 is to determine whether a pancreatic tumor is secreting it; if that is the case, then the levels should fall when the tumor is treated, and they may rise again if the disease recurs. CA19-9 antigen is highly expressed in Gastrointestinal (gastric, pancreatic, and colonic) Adenocarcinomas and salivary gland Mucoepidermoid Carcinomas. CA19-9 is usually not reactive with breast, kidney, and prostate Carcinomas, but is reactive with sialylated Lea-active pentasaccharide (sialylated lacto-N-fucopentaose II), which is enzymatically synthesized by sialylation of Type 1 carbohydrate chains.